UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------------------
FORM 12b-25
---------------------------
NOTIFICATION OF LATE FILING
SEC FILE NUMBER 000-32889
CUSIP NUMBER 46061X-10-6
(Check One):
[ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form N-SAR
For Period Ended: September 30, 2001
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________
- -------------------------------------------------------------------------------
Nothing in this form shall be construed to
imply that the Commission has verified any
information contained herein.
- -------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- -------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
INTERNATURAL PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
Full Name of Registrant
N/A
- --------------------------------------------------------------------------------
Former Name if Applicable
4201 Wilshire Boulevard, Suite 525
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Los Angeles, CA 90010
- --------------------------------------------------------------------------------
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rules 12b-25(b), the following
should be completed. (Check box if appropriate)
[ ] (a) The reasons described in reasonable detail in Part
III of this form could not be eliminated without
unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion
thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject
quarterly report of transition report on Form 10-Q, or
portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached applicable.
PART III -- NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, or the transition report portion thereof, could not be filed within the
prescribed time period. (Attach Extra Sheets if Needed)
The financial statements of the affiliates were not available in time for filing
of the consolidated report; therefore, the independent accountant is unable to
complete the review of the consolidated financial statements. (Please see
attached Exhibit 1)
PART IV-- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Lucille Abad
---------------------------------------------------------------------------
(Name)
(323)
---------------------------------------------------------------------------
(Area Code)
954-9808
---------------------------------------------------------------------------
(Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s).
[X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
[ ] Yes [X] No
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
- -------------------------------------------------------------------------------
INTERNATURAL PHARMACEUTICALS, INC.
--------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: November 13, 2001 By: /s/ Lucille Abad
----------------- ------------------------
Lucille Abad
President
* EXHIBIT 1 *
JOSEFINA C. DE LA CRUZ, C.P.A.
A PROFESSIONAL CORPORATION
Josefina C. de la Cruz, CPA 2700 N. Main Street, Suite 900
Rebecca Q. Masinsin, CPA Santa Ana, CA 92705
Timothy Vo, CPA Tel. No. (714) 558-8703
Marissa B. Zacarias, IT Manager Fax No. (714) 558-7940
- --------------------------------------------------------------------------------
-------------------------
C E R T I F I C A T I O N
-------------------------
This is to certify that we were unable to finish the review and issue an
independent accountant's report on the consolidated financial statements of
Internatural Pharmaceuticals, Inc. and Subsidiaries due to the unavailability of
affiliates' financial statements in time for filing of Form 10Q thereby
resulting to the filing of an extension.
JOSEFINA C. DE LA CRUZ, CPA
A Professional Corporation
November 13, 2001